Health

FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

DailyTrendDailyTrend
Jul 13, 2025 - 23:00
 0  0
FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, July 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt)...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Fragile N.C. Residents Lose Medicaid Support for Food and Housing

Fragile N.C. Residents Lose Medicaid Support for Food a...

DailyTrend Sep 30, 2025  0  0

Trump’s Pharma Tariffs Spare Richest Drugmakers

Trump’s Pharma Tariffs Spare Richest Drugmakers

DailyTrend Sep 26, 2025  0  0

What is a Medical Device Recall?

What is a Medical Device Recall?

DailyTrend Sep 30, 2025  0  0

Kennedy Says U.S. Rejects Global Health Goals

Kennedy Says U.S. Rejects Global Health Goals

DailyTrend Sep 25, 2025  0  0

How Trump’s Latest Tariffs May Affect Your Medicines

How Trump’s Latest Tariffs May Affect Your Medicines

DailyTrend Sep 26, 2025  0  0

Evkeeza (evinacumab-dgnb) Approved in the U.S. for Chil...

DailyTrend Sep 30, 2025  0  0